Anti-EGFR Therapy in Metastatic Colorectal Cancer: Identifying, Tracking, and Overcoming Resistance
Open accessThe DOI matches its Crossref record; 167 of the 167 references it cites were found in a registry or an index.
Abstract
Epidermal growth factor receptor (EGFR) inhibitors remain a cornerstone in the treatment of metastatic colorectal cancer with RAS and BRAF wild-type cancer. Yet, primary and acquired resistance limit their benefit for many patients. A growing body of evidence reveals that resistance is not random but rather driven by a complex network of molecular alterations that sustain tumor growth independent of EGFR signaling. These include amplification of ERBB2 (HER2) and MET, activation of the PI3K and AKT pathways, EGFR extracellular domain mutations, and rare kinase fusions. The concept of negative hyperselection has emerged as a powerful strategy to refine patient selection by excluding tumors with these resistance drivers. Multiple clinical trials have consistently shown that patients who are hyperselected based on comprehensive molecular profiling achieve significantly higher response rates and improved survival compared to those selected by RAS and BRAF status alone. Liquid biopsy through circulating tumor DNA has further transformed this landscape, offering a noninvasive tool to capture tumor heterogeneity, monitor clonal evolution in real time, and guide rechallenge strategies after resistance emerges. Together, negative hyperselection, ctDNA-guided monitoring, and emerging therapeutics define a precision-oncology framework for identifying, tracking, and overcoming resistance to anti-EGFR therapy in mCRC, moving the field toward more effective and individualized care. Looking ahead, the development of innovative therapeutics such as bispecific antibodies, antibody drug conjugates, and RNA-based therapies promises to further expand in this challenging clinical scenario. These advances move precision oncology in colorectal cancer from concept to clinical reality, reshaping the standard of care through molecular insights.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HER2 amplification activates the MEK-ERK (MAPK) and PI3K-AKT pathways, rendering EGFR signal blockade irrelevant [10].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PTEN deficiency has been reported in approximately 20–40% of patients with mCRC; however, variability in assessment methods and the lack of standardized testing have limited its implementation as a routine predictive biomarker [10,17].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“More resent trials, such as the phase III BREAKWATER trial (2024–2025), demonstrated that combination strategy of (a) encorafenib and cetuximab along with (b) chemotherapy, such as mFOLFOX6, has greatly improved the response rate and survival outcomes, supporting a shift toward biomarker-driven combination strategies in the first-line setting [10,73,74].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HER2 amplification occurs in approximately 2–5% of all mCRC cases; however, its frequency can rise up to ten to fifteen percent in the RAS wild-type population [10].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, there are several limitations, such as standardization, assay performance, economic feasibility, limited tumor shedding, restricted access to the bloodstream, and false negatives due to low shedding [10,83,84].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [10]
Experimental — accuracy not yet measured
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Colorectal cancer statistics, 2023
Siegel, R. L., Wagle, N. S., Cercek, A., Smith, R. A., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21772 · Cited by 3,733 · cited 1×
“In the United States, the American Cancer Society projects 153,000 new diagnoses and 52,550 for the year 2023, including almost 20,000 cases under the age of fifty [2].”
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824 · cited 1×
“RET fusions involve the RET (rearranged during transfection) kinase and are targeted by selective RET-inhibitors, including selpercatinib and pralsetinib [105].”
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788 · cited 1×
“These mutations drive resistance to anti-EGFR therapies by constitutively activating the MAPK pathway independent of EGFR-inhibition [92].”
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027 · cited 1×
“This arm supports metabolic reprogramming, protein synthesis, and resistance to apoptosis, which are key features of tumor survival [25].”
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889 · cited 1×
“Moreover, they may coexist with other genomic alterations that promote the activation of alternative signaling pathways, further compromising the efficacy of the anti-EGFR blockade [131].”
Cervantes, A., Adam, R., Roselló, S., Arnold, D., Normanno, N., Taïeb, J., Seligmann, J., De Baere, T., Osterlund, P., Yoshino, T., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.003 · Cited by 1,796
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713 · cited 1×
“These alterations may arise from the expansion of pre-existing mutated clones or from the emergence of new mutations induced by the selective pressure exerted by prolonged use of agents such as cetuximab or panitumumab [129,130].”
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
Siravegna, G., Mussolin, B., Buscarino, M., Corti, G., Cassingena, A., Crisafulli, G., Ponzetti, A., Cremolini, C., Amatu, A., Lauricella, C., et al. (2015) · Nature Medicine · doi:10.1038/nm.3870 · Cited by 1,082 · cited 1×
“In fact, CRC tumor consists of a complex population of distinct cellular clones that, over time, accumulate various genetic and epigenetic alterations, including mutations in oncogenes and tumor suppressor genes, DNA methylation changes, and variations in microRNA expression [122,123].”
Molecular cloning of a new transforming gene from a chemically transformed human cell line
Cooper, C. S., Park, M., Blair, D. G., Tainsky, M. A., Huebner, K., Croce, C. M., & Vande Woude, G. F. (1984) · Nature · doi:10.1038/311029a0 · Cited by 989 · cited 2×
“The PRESSING2 study employed an expanded molecular panel to identify uncommon genomic alterations in RAS wild-type mCRC patients undergoing anti-EGFR therapy [87].”
Mutant PIK3CA promotes cell growth and invasion of human cancer cells.
Samuels, Y., Diaz, L. A., Schmidt-Kittler, O., Cummins, J. M., DeLong, L., Cheong, I., Rago, C., Huso, D. L., Lengauer, C., Kinzler, K. W., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.014 · Cited by 915 · cited 1×
“In parallel, alterations in PIK3CA or loss of PTEN hyperac-tivate the AKT pathway, promoting survival and resistance to apoptosis [31,32].”
Van Cutsem, E., Lenz, H.-J., Köhne, C.-H., Heinemann, V., Tejpar, S., Melezínek, I., Beier, F., Stroh, C., Rougier, P., van Krieken, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4812 · Cited by 789
Sartore-Bianchi, A., Martini, M., Molinari, F., Veronese, S., Nichelatti, M., Artale, S., Di Nicolantonio, F., Saletti, P., De Dosso, S., Mazzucchelli, L., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2466 · Cited by 739
Di Fiore, F., Blanchard, F., Charbonnier, F., Le Pessot, F., Lamy, A., Galais, M. P., Bastit, L., Killian, A., Sesboüé, R., Tuech, J. J., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603685 · Cited by 734
Tejpar, S., Stintzing, S., Ciardiello, F., Tabernero, J., Van Cutsem, E., Beier, F., Esser, R., Lenz, H.-J., & Heinemann, V. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3797 · Cited by 709 · cited 1×
“Tumors that retain the wild-type presentation of these genes are considered eligible for epidermal growth factor receptor (EGFR) blockade with cetuximab or panitumumab, particularly in left-sided tumors [10,11].”
Treatment of Metastatic Colorectal Cancer: ASCO Guideline
Morris, V. K., Kennedy, E. B., Baxter, N. N., Benson, A. B., Cercek, A., Cho, M., Ciombor, K. K., Cremolini, C., Davis, A., Deming, D. A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01690 · Cited by 682 · cited 1×
“International guidelines from societies such as the American Society of Clinical Oncology (ASCO), European Society of Clinical Oncology (ESMO), and National Comprehensive Cancer Network (NCCN) recommend routine testing for mutations in KRAS , NRAS , and BRAF [7–9].”
Laurent-Puig, P., Cayre, A., Manceau, G., Buc, E., Bachet, J.-B., Lecomte, T., Rougier, P., Lievre, A., Landi, B., Boige, V., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6796 · Cited by 673
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab
Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002442 · Cited by 663 · cited 1×
“HER2 overexpression actiular sequencing, such as NGSvates downstream signaling, independently of EGFR, bypassed the necessity for EGFR signaling and thus rendered EGFR inhibitors ineffective [67,68].”
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
Bardelli, A., Corso, S., Bertotti, A., Hobor, S., Valtorta, E., Siravegna, G., Sartore-Bianchi, A., Scala, E., Cassingena, A., Zecchin, D., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0558 · Cited by 657 · cited 2×
“Interestingly, the traditional expansion of ‘MET’ as ‘mesenchymal–epithelial transition factor’ is a common misnomer [85]; the official HGNC designation is ‘MET proto-oncogene,’ and the original ‘met’ acronym was a neutral label from the MNNG-HOS transforming gene [86].”
Sharma, R., Abbasi-Kangevari, M., Abd-Rabu, R., Abidi, H., Abu-Gharbieh, E., Acuna, J. M., Adhikari, S., Advani, S. M., Afzal, M. S., Aghaie Meybodi, M., et al. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00044-9 · Cited by 650
Douillard, J. Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu141 · Cited by 606 · cited 1×
“Direct comparison in the ASPECCT trial confirmed similar outcomes for these drugs, with OS of 10.4 months for panitumumab and 10 months for cetuximab, and fewer severe infusion reactions with the fully human antibody [44].”
InfluentialEGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance
Uribe, M. L., Marrocco, I., & Yarden, Y. (2021) · Cancers · doi:10.3390/cancers13112748 · Cited by 604 · cited 1×
“In its inactive state, the extracellular domain adopts a folded conformation that holds the receptor in a monomeric and catalytically silent configuration [19,20].”
Bokemeyer, C., Cutsem, E. V., Rougier, P., Ciardiello, F., Heeger, S., Schlichting, M., Celik, I., & Köhne, C.-H. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.02.057 · Cited by 585 · cited 1×
“Randomized trials demonstrate that the addition of an anti-EGFR antibody to fluoropyrimidine-based doublet or triplet chemotherapy improves response rate and progression-free survival (PFS) compared with chemotherapy alone, and can extend overall survival (OS) in selected patients [12,13].”
Meric-Bernstam, F., Hurwitz, H., Raghav, K. P. S., McWilliams, R. R., Fakih, M., VanderWalde, A., Swanton, C., Kurzrock, R., Burris, H., Sweeney, C., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30904-5 · Cited by 573
Difference Between Left-Sided and Right-Sided Colorectal Cancer: A Focused Review of Literature
Baran, B., Mert Ozupek, N., Yerli Tetik, N., Acar, E., Bekcioglu, O., & Baskin, Y. (2018) · Gastroenterology Research · doi:10.14740/gr1062w · Cited by 553 · cited 1×
“Tumors with BRAF V600E mutations and without microsatellite instability should be treated with FOLFOX, encorafenib, and cetuximab according to the recently published BREAKWATER trial [51].”
Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy
Li, Q., Geng, S., Luo, H., Wang, W., Mo, Y.-Q., Luo, Q., Wang, L., Song, G.-B., Sheng, J.-P., & Xu, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01953-7 · Cited by 546 · cited 1×
“In its inactive state, the extracellular domain adopts a folded conformation that holds the receptor in a monomeric and catalytically silent configuration [19,20].”
Spatial control of EGF receptor activation by reversible dimerization on living cells
Chung, I., Akita, R., Vandlen, R., Toomre, D., Schlessinger, J., & Mellman, I. (2010) · Nature · doi:10.1038/nature08827 · Cited by 538 · cited 1×
“These phosphorylated tyrosines act as docking sites for a variety of adaptor proteins that initiate multiple downstream signaling cascades [23].”
Holch, J. W., Ricard, I., Stintzing, S., Modest, D. P., & Heinemann, V. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.10.007 · Cited by 534 · cited 1×
“In right-sided disease, the same antibodies failed to outperform the vascular–endothelial–growth-factor blockade, even when molecularly selected, an observation ascribed to differential embryologic origin, microbiome composition, and cytokine milieu [49,50].”
Resistance to anti-EGFR therapy in colorectal cancer: From heterogeneity to convergent evolution
Misale, S., Di Nicolantonio, F., Sartore-Bianchi, A., Siena, S., & Bardelli, A. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0462 · Cited by 513 · cited 2×
“MET amplification is rare, occurring in 1–2% of CRC tumors [14,88].”
Montagut, C., Dalmases, A., Bellosillo, B., Crespo, M., Pairet, S., Iglesias, M., Salido, M., Gallen, M., Marsters, S., Tsai, S. P., et al. (2012) · Nature Medicine · doi:10.1038/nm.2609 · Cited by 513 · cited 1×
“The identification of the main molecular alterations responsible for this resistance has been a priority for the development of personalized therapeutic strategies, prompting a series of clinical trials aimed at understanding the mechanisms involved in acquired resistance [125–127].”
Pietrantonio, F., Petrelli, F., Coinu, A., Di Bartolomeo, M., Borgonovo, K., Maggi, C., Cabiddu, M., Iacovelli, R., Bossi, I., Lonati, V., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.01.054 · Cited by 486 · cited 1×
“In a retrospective subgroup of the FIRE-3 trial, patients with BRAF -mutant tumors achieved almost identical median OS and PFS whether treated with FOLFIRI plus cetuximab or FOLFIRI plus bevacizumab [63].”
Price, T. J., Peeters, M., Kim, T. W., Li, J., Cascinu, S., Ruff, P., Suresh, A. S., Thomas, A., Tjulandin, S., Zhang, K., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70118-4 · Cited by 473 · cited 1×
“However, it was noted that the clinical benefit was strictly contingent on molecular context [45].”
Targeting Alterations in the RAF–MEK Pathway
Yaeger, R., & Corcoran, R. B. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1321 · Cited by 465 · cited 1×
“In parallel, alterations in PIK3CA or loss of PTEN hyperac-tivate the AKT pathway, promoting survival and resistance to apoptosis [31,32].”
Impact of EGFR expression on colorectal cancer patient prognosis and survival
Spano, J.-P., Lagorce, C., Atlan, D., Milano, G., Domont, J., Benamouzig, R., Attar, A., Benichou, J., Martin, A., Morere, J.-F., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi006 · Cited by 462 · cited 1×
“Similarly, the BRAFV600E mutation acts further downstream to provide a continuous growth signal independent of receptor activation [29,30].”
Jhawer, M., Goel, S., Wilson, A. J., Montagna, C., Ling, Y.-H., Byun, D.-S., Nasser, S., Arango, D., Shin, J., Klampfer, L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5659 · Cited by 460 · cited 1×
“These molecular alterations not only drive tumor progression but also predict poor response to EGFR-targeted therapies, significantly influencing both prognosis and treatment outcomes [33,34].”
Antibody-Dependent Cellular Cytotoxicity Mediated by Cetuximab against Lung Cancer Cell Lines
Kurai, J., Chikumi, H., Hashimoto, K., Yamaguchi, K., Yamasaki, A., Sako, T., Touge, H., Makino, H., Takata, M., Miyata, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1726 · Cited by 435
Saltz, L. B., Lenz, H.-J., Kindler, H. L., Hochster, H. S., Wadler, S., Hoff, P. M., Kemeny, N. E., Hollywood, E. M., Gonen, M., Quinones, M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0949 · Cited by 425 · cited 1×
“In the first-line CRYSTAL study, cetuximab combined with FOLFIRI raised response from 40% to 59% and extended PFS from 8 to 10 months among tumors harboring wild-type KRAS [42].”
Perrone, F., Lampis, A., Orsenigo, M., Di Bartolomeo, M., Gevorgyan, A., Losa, M., Frattini, M., Riva, C., Andreola, S., Bajetta, E., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn541 · Cited by 410 · cited 1×
“The prognostic role of PIK3CA mutations were evaluated in a recent meta-analysis of four randomized controlled trials [83].”
Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer
Russo, M., Siravegna, G., Blaszkowsky, L. S., Corti, G., Crisafulli, G., Ahronian, L. G., Mussolin, B., Kwak, E. L., Buscarino, M., Lazzari, L., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1283 · Cited by 405 · cited 1×
“Although less frequent, secondary mutations also contribute significantly to acquired resistance to anti-EGFR therapy [132].”
Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond
Keller, L., Belloum, Y., Wikman, H., & Pantel, K. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01047-5 · Cited by 401 · cited 1×
“Turnaround time, although generally shorter than that of tissue-based sequencing, may still be suboptimal due to logistical delays in sample handling and reporting [161,162].”
Signaling pathways involved in colorectal cancer progression
Koveitypour, Z., Panahi, F., Vakilian, M., Peymani, M., Seyed Forootan, F., Nasr Esfahani, M. H., & Ghaedi, K. (2019) · Cell & Bioscience · doi:10.1186/s13578-019-0361-4 · Cited by 393 · cited 1×
“Recruitment of phospholipase C gamma generates diacylglycerol and inositol trisphosphate, elevating intracellular calcium and activating protein kinase C, which is involved in regulating cell motility [26].”
Nakamura, Y., Taniguchi, H., Ikeda, M., Bando, H., Kato, K., Morizane, C., Esaki, T., Komatsu, Y., Kawamoto, Y., Takahashi, N., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1063-5 · Cited by 373 · cited 1×
“Turnaround time, although generally shorter than that of tissue-based sequencing, may still be suboptimal due to logistical delays in sample handling and reporting [161,162].”
Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Adam, M., Chang, G., Chen, Y.-J., Ciombor, K. K., Cohen, S. A., Cooper, H. S., Deming, D., Garrido-Laguna, I., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.0029 · Cited by 371 · cited 2×
“International guidelines from societies such as the American Society of Clinical Oncology (ASCO), European Society of Clinical Oncology (ESMO), and National Comprehensive Cancer Network (NCCN) recommend routine testing for mutations in KRAS , NRAS , and BRAF [7–9].”
Sung, H., Siegel, R. L., Laversanne, M., Jiang, C., Morgan, E., Zahwe, M., Cao, Y., Bray, F., & Jemal, A. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00600-4 · Cited by 366 · cited 2×
“…overall mortality continues to decline at roughly 2% per year, incidence in adults younger than 55 years has been rising by about one to two percent annually since the mid-nineteen nineties, and late-stage presentation is again increasing after years of progress toward earlier detection [3].”
EGFR signaling pathway as therapeutic target in human cancers
Levantini, E., Maroni, G., Del Re, M., & Tenen, D. G. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.04.002 · Cited by 356 · cited 1×
“This triggers the RAF–MEK–ERK cascade, driving gene transcription necessary for cell cycle progression and proliferation [24].”
Ciardiello, F., Bianco, R., Caputo, R., Caputo, R., Damiano, V., Troiani, T., Melisi, D., De Vita, F., De Placido, S., Bianco, A. R., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1100-03 · Cited by 347
Clinical Development of BRAF plus MEK Inhibitor Combinations
Subbiah, V., Baik, C., & Kirkwood, J. M. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.05.009 · Cited by 344 · cited 1×
“Additionally, mutations in BRAF , a member of the RAF serine/threonine kinase family, promote continuous activation of the RAF-ERK pathway, constituting an important mechanism of acquired resistance [134,135].”
STAT‐mediated EGFR signaling in cancer
Quesnelle, K. M., Boehm, A. L., & Grandis, J. R. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21475 · Cited by 295 · cited 1×
“Overexpression together with abundant autocrine ligand promotes sustained signaling that correlates with poor differentiation, early relapse, and reduced survival [28].”
Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices
Malla, M., Loree, J. M., Kasi, P. M., & Parikh, A. R. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02615 · Cited by 292 · cited 2×
“Its sensitivity is affected by tumor biology and assay performance [156–158].”
Watanabe, J., Muro, K., Shitara, K., Yamazaki, K., Shiozawa, M., Ohori, H., Takashima, A., Yokota, M., Makiyama, A., Akazawa, N., et al. (2023) · JAMA · doi:10.1001/jama.2023.4428 · Cited by 280 · cited 1×
“In right-sided disease, the same antibodies failed to outperform the vascular–endothelial–growth-factor blockade, even when molecularly selected, an observation ascribed to differential embryologic origin, microbiome composition, and cytokine milieu [49,50].”
Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
Arena, S., Bellosillo, B., Siravegna, G., Martínez, A., Cañadas, I., Lazzari, L., Ferruz, N., Russo, M., Misale, S., González, I., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2821 · Cited by 271 · cited 1×
“Genetic alterations in KRAS , such as mutations and amplifications, are present in approximately 50% of cases and represent the main mechanism of acquired resistance in this scenario [128].”
Sartore-Bianchi, A., Pietrantonio, F., Lonardi, S., Mussolin, B., Rua, F., Crisafulli, G., Bartolini, A., Fenocchio, E., Amatu, A., Manca, P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01886-0 · Cited by 268
Strickler, J. H., Cercek, A., Siena, S., André, T., Ng, K., Van Cutsem, E., Wu, C., Paulson, A. S., Hubbard, J. M., Coveler, A. L., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00150-x · Cited by 259 · cited 1×
“Additionally, the HERACLES trial evaluated trastuzumab plus lapatinib, the MyPathway study investigated trastuzumab plus pertuzumab, and the MOUNTAINEER trial assessed trastuzumab plus tucatinib, all demonstrating meaningful responses in heavily pretreated HER2-positive mCRC [72–74].”
Woolston, A., Khan, K., Spain, G., Barber, L. J., Griffiths, B., Gonzalez-Exposito, R., Hornsteiner, L., Punta, M., Patil, Y., Newey, A., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.05.013 · Cited by 254 · cited 1×
“Additional preclinical data indicate that cancer-associated fibroblasts (CAF), through the secretion of various soluble factors, play a central role in inducing resistance to EGFR blockade [137,138].”
Subbiah, V., Cassier, P. A., Siena, S., Garralda, E., Paz-Ares, L., Garrido, P., Nadal, E., Vuky, J., Lopes, G., Kalemkerian, G. P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01931-y · Cited by 247 · cited 1×
“Both gene rearrangements drive ligand-independent activation of the MAPK and PI3K-AKT signaling pathways, bypassing EGFR-inhibition and contributing to resistance to anti-EGFR therapies [106].”
Zhou, J., Ji, Q., & Li, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02130-2 · Cited by 246 · cited 2×
“Exploratory analyses of the randomized phase II PanaMa trial evaluated the role of negative hyperselection in maintenance therapy with panitumumab in patients with RAS wild-type mCRC [140].”
Nakamura, Y., Okamoto, W., Kato, T., Esaki, T., Kato, K., Komatsu, Y., Yuki, S., Masuishi, T., Nishina, T., Ebi, H., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01553-w · Cited by 231 · cited 1×
“HER2-directed therapies are rapidly becoming a new standard of care for this molecularly defined subset [77].”
Martinelli, E., Ciardiello, D., Martini, G., Troiani, T., Cardone, C., Vitiello, P. P., Normanno, N., Rachiglio, A. M., Maiello, E., Latiano, T., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.10.007 · Cited by 225 · cited 2×
“A considerable fraction of patients with KRAS , NRAS , and BRAF wild-type tumors derive little or no advantage from anti-EGFR therapy, and acquired resistance commonly emerges within months of treatment initiation [14,15].”
Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial
Tian, J., Chen, J. H., Chao, S. X., Pelka, K., Giannakis, M., Hess, J., Burke, K., Jorgji, V., Sindurakar, P., Braverman, J., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02181-8 · Cited by 198 · cited 1×
“Activating mutations in AKT1 are rare in mCRC, found in less than 2% of cases [95].”
Sartore-Bianchi, A., Lonardi, S., Martino, C., Fenocchio, E., Tosi, F., Ghezzi, S., Leone, F., Bergamo, F., Zagonel, V., Ciardiello, F., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000911 · Cited by 185
EGFR Signaling in Colorectal Carcinoma
Krasinskas, A. M. (2011) · Pathology Research International · doi:10.4061/2011/932932 · Cited by 184 · cited 1×
“Dimerization brings together the intracellular kinase domains into an asymmetric alignment, where one kinase lobe activates the other, leading to autophosphorylation of tyrosine residues on the cytoplasmic tail [21,22].”
Yoshino, T., Di Bartolomeo, M., Raghav, K., Masuishi, T., Loupakis, F., Kawakami, H., Yamaguchi, K., Nishina, T., Wainberg, Z., Elez, E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38032-4 · Cited by 178 · cited 1×
“Additionally, the HERACLES trial evaluated trastuzumab plus lapatinib, the MyPathway study investigated trastuzumab plus pertuzumab, and the MOUNTAINEER trial assessed trastuzumab plus tucatinib, all demonstrating meaningful responses in heavily pretreated HER2-positive mCRC [72–74].”
Mohan, S., Heitzer, E., Ulz, P., Lafer, I., Lax, S., Auer, M., Pichler, M., Gerger, A., Eisner, F., Hoefler, G., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004271 · Cited by 177 · cited 2×
“Beyond genomic alterations, there is evidence that acquired resistance may also be mediated by transcriptomic profiles associated with epithelial–mesenchymal transition, characterizing a pattern of cross-resistance [137].”
The biological properties of cetuximab
Vincenzi, B., Schiavon, G., Silletta, M., Santini, D., & Tonini, G. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.07.006 · Cited by 168 · cited 1×
“…three complementary mechanisms: blockade of ligand-induced signaling, lysosomal degradation of cell-surface receptors, and engagement of immune effector cells through the Fc region (antibody-dependent cellular cytotoxicity is more pronounced with cetuximab because of its IgG-one backbone) [36,38].”
Encorafenib, Cetuximab, and mFOLFOX6 in BRAF -Mutated Colorectal Cancer
Elez, E., Yoshino, T., Shen, L., Lonardi, S., Van Cutsem, E., Eng, C., Kim, T. W., Wasan, H. S., Desai, J., Ciardiello, F., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2501912 · Cited by 166
MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms
Wu, P., & Park, J. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.023 · Cited by 156 · cited 1×
“Both patients received panitumumab monotherapy as third-line treatment and showed primary resistance, with clinical benefit observed only when anti-EGFR agents were combined with cytotoxic chemotherapy [93].”
Fracasso, P. M., Burris, H., Arquette, M. A., Govindan, R., Gao, F., Wright, L. P., Goodner, S. A., Greco, F. A., Jones, S. F., Willcut, N., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1542 · Cited by 153 · cited 1×
“In the past decades, early single-arm studies demonstrated activity in chemotherapy-refractory disease, paving the way for randomized evaluations [39,40].”
Stintzing, S., Miller‐Phillips, L., Modest, D. P., von Weikersthal, L. F., Decker, T. W., Kiani, A., Vehling‐Kaiser, U., Al-Batran, S.-E., Heintges, T., Kahl, C., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.03.023 · Cited by 152 · cited 1×
“5 study then directly compared first-line FOLFOXIRI plus bevacizumab against FOLFOXIRI plus cetuximab in BRAFV600E-mutant mCRC, finding significantly longer PFS (6.7 months v 10.7 months; HR, 1.89; 95% CI, 1.19 to 3.01, 1.89; p = 0.006) with bevacizumab despite similar response rates [64].”
InfluentialMayer, E. L., Ren, Y., Wagle, N., Mahtani, R. L., Ma, C. X., DeMichele, A. M., Cristofanilli, M., Meisel, J. L., Miller, K. D., Abdou, Y. G., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01940 · Cited by 151 · cited 1×
“Many AKT inhibitors, AZD5363, GDC-0068, and MK2006, have been tested in early clinical trials [99–101].”
Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias
Kim, M. S., Jeong, E. G., Yoo, N. J., & Lee, S. H. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604212 · Cited by 140 · cited 1×
“These mutations enable alternative signaling pathways that bypass EGFR dependency, contributing to resistance against anti-EGFR treatments [96].”
Montagut, C., Argilés, G., Ciardiello, F., Poulsen, T. T., Dienstmann, R., Kragh, M., Kopetz, S., Lindsted, T., Ding, C., Vidal, J., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5245 · Cited by 135 · cited 1×
“Additionally, mutations in BRAF , a member of the RAF serine/threonine kinase family, promote continuous activation of the RAF-ERK pathway, constituting an important mechanism of acquired resistance [134,135].”
Targeting the EGFR signaling pathway in cancer therapy: What’s new in 2023?
Halder, S., Basu, S., Lall, S. P., Ganti, A. K., Batra, S. K., & Seshacharyulu, P. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2218613 · Cited by 133 · cited 2×
“…three complementary mechanisms: blockade of ligand-induced signaling, lysosomal degradation of cell-surface receptors, and engagement of immune effector cells through the Fc region (antibody-dependent cellular cytotoxicity is more pronounced with cetuximab because of its IgG-one backbone) [36,38].”
Raghav, K., Loree, J. M., Morris, J. S., Overman, M. J., Yu, R., Meric-Bernstam, F., Menter, D., Korphaisarn, K., Kee, B., Muranyi, A., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00226 · Cited by 132 · cited 1×
“A recent meta-analysis of five retrospective cohort studies involving 594 patients with RAS wild-type mCRC demonstrated that HER2-positive tumors treated with anti-EGFR agents exhibited significantly worse PFS (HR 2.84; 95% CI, 1.44–5.60) and ORR (HR 1.96; 95% CI 1.10–3.48) [70].”
InfluentialDose and Schedule Study of Panitumumab Monotherapy in Patients with Advanced Solid Malignancies
Weiner, L. M., Belldegrun, A. S., Crawford, J., Tolcher, A. W., Lockbaum, P., Arends, R. H., Navale, L., Amado, R. G., Schwab, G., & Figlin, R. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1509 · Cited by 125 · cited 1×
“The BOND trial showed that adding cetuximab to irinotecan after prior failure doubled objective response to 23% and tripled PFS to 4.1 months [41].”
InfluentialEncorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial
Kopetz, S., Yoshino, T., Van Cutsem, E., Eng, C., Kim, T. W., Wasan, H. S., Desai, J., Ciardiello, F., Yaeger, R., Maughan, T. S., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03443-3 · Cited by 124 · cited 1×
“…conjugates (ADCs) that link EGFR recognition to cytotoxic payloads, bispecific antibodies that co-target EGFR and c-MET or EGFR and HER3, and small interfering RNA nanocomplexes that selectively silence mutant RAS are entering early-phase trials, while their results are awaited [52–57].”
Day, F. L., Jorissen, R. N., Lipton, L., Mouradov, D., Sakthianandeswaren, A., Christie, M., Li, S., Tsui, C., Tie, J., Desai, J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3614 · Cited by 124 · cited 1×
“They are found in approximately 10–20% of CRC, with hotspots in exon 9 and exon 20 [80].”
Zhai, Z., Yu, X., Yang, B. J., Zhang, Y., Zhang, L., Li, X., & Sun, H. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.08.033 · Cited by 120 · cited 2×
“In fact, CRC tumor consists of a complex population of distinct cellular clones that, over time, accumulate various genetic and epigenetic alterations, including mutations in oncogenes and tumor suppressor genes, DNA methylation changes, and variations in microRNA expression [122,123].”
Oliveira, K. C. D. S., Ramos, I. B., da Silva, J. M. C., Barra, W. F., Riggins, G. J., Palande, V., Pinho, C. T., Frenkel‐Morgenstern, M., Santos, S., de Assumpção, P. P., et al. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0768 · Cited by 115 · cited 1×
“…DNA from multiple sites, enables real-time monitoring of tumor evolution and treatment response (including early detection of resistance), serves as a sensitive marker for minimal residual disease (MRD) post-treatment to predict recurrence, and potentially offers faster turnaround times [150–153].”
Morano, F., Corallo, S., Lonardi, S., Raimondi, A., Cremolini, C., Rimassa, L., Murialdo, R., Zaniboni, A., Sartore-Bianchi, A., Tomasello, G., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01254 · Cited by 111 · cited 1×
“Repeated biopsy is often impractical, sometimes impossible, and it cannot reveal the dynamic rise and fall of subclones that ultimately determine clinical outcome [147].”
Targeting the EGFR signalling pathway in metastatic colorectal cancer
Napolitano, S., Martini, G., Ciardiello, D., Tufo, S. D., Martinelli, E., Troiani, T., & Ciardiello, F. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00479-x · Cited by 108 · cited 1×
“This molecular heterogeneity has reshaped how metastatic CRC (mCRC) is treated, moving beyond one-size-fits-all approaches toward strategies guided by tumor biology [5,6].”
Mao, C., Liao, R.-Y., Qiu, L., Wang, X.-W., Ding, H., & Chen, Q. (2010) · Molecular Biology Reports · doi:10.1007/s11033-010-0351-4 · Cited by 100 · cited 1×
“In left-sided primaries that retain wild-type RAS and BRAF , cetuximab or panitumumab combined with doublet chemotherapy achieves median OS beyond 35 months, surpassing outcomes obtained with bevacizumab-containing regimens [48].”
Cao, Z., Quazi, S., Arora, S., Osellame, L. D., Burvenich, I. J. G., Janes, P. W., & Scott, A. M. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-024-01099-2 · Cited by 100 · cited 1×
“In other words, even after the traditional selection based on RAS and BRAF and tumor sidedness, approximately one-third of patients do not respond to EGFR -inhibition, indicating that additional molecular escape mechanisms limit therapeutic efficacy [142].”
Sun, L. J., Huang, Y., Liu, Y., Zhao, Y., He, X., Zhang, L., Wang, F., & Zhang, Y. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0943-9 · Cited by 92
Guo, L., Wang, Y., Yang, W., Wang, C., Guo, T., Yang, J., Shao, Z., Cai, G., Cai, S., Zhang, L., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.04.029 · Cited by 92 · cited 1×
“This molecular heterogeneity has reshaped how metastatic CRC (mCRC) is treated, moving beyond one-size-fits-all approaches toward strategies guided by tumor biology [5,6].”
Garvey, C. M., Lau, R., Sanchez, A., Sun, R. X., Fong, E. J., Doche, M. E., Chen, O., Jusuf, A., Lenz, H.-J., Larson, B., et al. (2020) · Cancers · doi:10.3390/cancers12061393 · Cited by 83 · cited 1×
“Key CAF-derived factors implicated in anti-EGFR resistance include HGF (activates MET and sustains MAPK/PI3K–AKT signaling), TGF-β (promotes EMT and adaptive tolerance), IL-6/IL-8 (STAT3-mediated survival/inflammation), FGF2 (FGFR signaling), and neuregulin-1 (HER3/HER2 activation) [139].”
Prognostic value of c-Met in colorectal cancer: A meta-analysis
Liu, Y. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i12.3706 · Cited by 83
Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer
Dienstmann, R., Salazar, R., & Tabernero, J. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e149 · Cited by 82 · cited 2×
“It expands molecular profiling beyond the standard evaluation of RAS and BRAF , aiming to identify additional biomarkers of primary resistance, such as ERBB2 amplification, MET amplification, and rare oncogenic fusions before treat-ment begins [16].”
Bray, S. M., Lee, J., Kim, S. T., Hur, J. Y., Ebert, P. J., Calley, J. N., Wulur, I. H., Gopalappa, T., Wong, S. S., Qian, H.-R., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-51981-5 · Cited by 82
Larribère, L., & Martens, U. M. (2021) · Cancers · doi:10.3390/cancers13225698 · Cited by 82
Kato, S., Okamura, R., Mareboina, M., Lee, S., Goodman, A. M., Patel, S. P., Fanta, P. T., Schwab, R. B., Vu, P., Raymond, V. M., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00180 · Cited by 77 · cited 1×
“…BRAF when tissue is limited), monitoring response and resistance (detecting changes in mutation frequency and emergence of new resistance mechanisms like EGFR ECD mutations), and guiding rechallenge strategies based on the presence or absence of prior resistance mutations [60,154,155] (Figure 3).”
Raghav, K., Morris, V., Tang, C., Morelli, P., Amin, H. M., Chen, K., Manyam, G. C., Broom, B., Overman, M. J., Shaw, K., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10559 · Cited by 77 · cited 1×
“Despite this, survival outcomes were encouraging, with a median PFS of 2.6 months and a median OS of 9.2 months [90].”
InfluentialBoustany, L. M., LaPorte, S. L., Wong, L., White, C. W., Vinod, V., Shen, J., Yu, W., Koditek, D., Winter, M. B., Moore, S. J., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-2483 · Cited by 75 · cited 1×
“Concurrently, emerging modalities, including bispecific antibodies, EGFR-directed antibody–drug conjugates, and RNA-based therapeutics will expand the options for patients with resistant disease [53,158,165,166].”
Eng, C., Bessudo, A., Hart, L. L., Severtsev, A., Gladkov, O., Müller, L., Kopp, M. V., Vladimirov, V., Langdon, R., Kotiv, B., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30049 · Cited by 72 · cited 1×
“MAP2K1 is the gene that encodes the protein MEK1 , a serine/threonine protein kinase that acts downstream of RAS in the RAS-RAF-MEK-ERK pathway [91].”
Stintzing, S., Heinrich, K., Tougeron, D., Modest, D. P., Schwaner, I., Eucker, J., Pihusch, R., Stauch, M., Kaiser, F., Kahl, C., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01420 · Cited by 69 · cited 1×
“In recognition of this clinical significance difference, NCCN and ESMO guidelines now recommend testing for KRAS , NRAS , and BRAFV600E mutations to guide the selection of first-line and subsequent therapies [9,65].”
The role of PIK3CA gene mutations in colorectal cancer and the selection of treatment strategies
Wang, H., Tang, R., Ling, J., & Jia, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1494802 · Cited by 65 · cited 1×
“PIK3CA mutations and PTEN loss activate the PI3K/AKT pathway, promoting tumor survival through mechanisms independent of EGFR [78,79].”
EGFR-directed antibodies promote HER2 ADC internalization and efficacy
Gupta, A., Michelini, F., Shao, H., Yeh, C., Drago, J. Z., Liu, D., Rosiek, E., Romin, Y., Ghafourian, N., Thyparambil, S. P., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101792 · Cited by 65 · cited 1×
“PIK3CA mutations and PTEN loss activate the PI3K/AKT pathway, promoting tumor survival through mechanisms independent of EGFR [78,79].”
RNA-based therapeutics for colorectal cancer: Updates and future directions
Liu, J., & Guo, B. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104550 · Cited by 62 · cited 1×
“Concurrently, emerging modalities, including bispecific antibodies, EGFR-directed antibody–drug conjugates, and RNA-based therapeutics will expand the options for patients with resistant disease [53,158,165,166].”
Dual PI3K/mTOR Inhibition in Colorectal Cancers with APC and PIK3CA Mutations
Foley, T. M., Payne, S. N., Pasch, C. A., Yueh, A. E., Van De Hey, D. R., Korkos, D. P., Clipson, L., Maher, M. E., Matkowskyj, K. A., Newton, M. A., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0256 · Cited by 62
Accuracy of preoperative staging with multidetector computed tomography in colon cancer
Olsen, A. S. F., Gundestrup, A. K., Kleif, J., Thanon, T., & Bertelsen, C. A. (2020) · Colorectal Disease · doi:10.1111/codi.15415 · Cited by 62 · cited 2×
“…(adult phase 1, pediatric phase 1–2, adult/adolescent phase 2), with an overall response rate of 75% (95% CI, 61–85) by independent review; at 1 year, 71% of responses were ongoing and 55% of patients remained progression-free, with no discontinuations due to drug-related adverse events [103].”
Van Cutsem, E., Lang, I., Folprecht, G., Nowacki, M., Barone, C., Shchepotin, I., Maurel, J., Cunningham, D., Celik, I., & Kohne, C. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3570 · Cited by 61
The Evolving Treatment Landscape in BRAF-V600E–Mutated Metastatic Colorectal Cancer
Tabernero, J., Ros, J., & Élez, E. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_349561 · Cited by 59
Tan, L., Tran, B., Tie, J., Markman, B., Ananda, S., Tebbutt, N. C., Michael, M., Link, E. K., Wong, S. Q., Chandrashekar, S., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3094 · Cited by 59
Valenza, C., Saldanha, E. F., Gong, Y., Placido, P. D., Gritsch, D., Ortiz, H., Trapani, D., Conforti, F., Cremolini, C., Peters, S., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.03.019 · Cited by 59 · cited 1×
“False-negative results may occur in cases with low tumor burden, limited tumor shedding, or metastases located in compartments with restricted access to the bloodstream, such as the peritoneum or central nervous system [159,160].”
Daly, C., Castanaro, C., Zhang, W., Zhang, Q., Wei, Y., Ni, M., Young, T. M., Zhang, L., Burova, E., & Thurston, G. (2017) · Oncogene · doi:10.1038/onc.2016.216 · Cited by 58 · cited 1×
“NTRK fusions involve the TRK family ( NTRK1–3 ) and are pan-tumor biomarkers effectively targeted by TRK-inhibitors such as larotrectinib and entrectinib [104].”
Randon, G., Maddalena, G., Germani, M. M., Pircher, C. C., Manca, P., Bergamo, F., Giordano, M., Sposetti, C., Montagna, A., Vetere, G., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.22.00037 · Cited by 54 · cited 1×
“MET amplification is rare, occurring in 1–2% of CRC tumors [14,88].”
EGFR trafficking: effect of dimerization, dynamics, and mutation
Schultz, D. F., Billadeau, D. D., & Jois, S. D. S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1258371 · Cited by 52 · cited 1×
“Dimerization brings together the intracellular kinase domains into an asymmetric alignment, where one kinase lobe activates the other, leading to autophosphorylation of tyrosine residues on the cytoplasmic tail [21,22].”
Rimassa, L., Bozzarelli, S., Pietrantonio, F., Cordio, S., Lonardi, S., Toppo, L., Zaniboni, A., Bordonaro, R., Di Bartolomeo, M., Tomasello, G., et al. (2019) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2019.02.004 · Cited by 50
Intratumor Heterogeneity: Novel Approaches for Resolving Genomic Architecture and Clonal Evolution
Gupta, R. G., & Somer, R. A. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0070 · Cited by 50 · cited 1×
“…sufficient quantity and quality of tumor tissue, often compounded by tumor location or the patient’s condition [122,148]. ctDNA, small DNA fragments shed by tumors into the bloodstream, allows for non-invasive liquid biopsies for genomic profiling via molecular sequencing, such as NGS [149].”
State-of-the-Art Management of Colorectal Cancer: Treatment Advances and Innovation
Pathak, P., Chan, G. H. J., Deming, D. A., & Chee, C. E. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_438466 · Cited by 49 · cited 1×
“Financial and infrastructural barriers also limit access to ctDNA testing in many healthcare settings [163].”
Rowland, A., Dias, M. M., Wiese, M. D., Kichenadasse, G., McKinnon, R. A., Karapetis, C. S., & Sorich, M. J. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.025 · Cited by 48 · cited 1×
“Analyses of every pivotal study showed no advantage in tumors carrying activating mutations in KRAS or NRAS exons 2, 3, or 4, or BRAFV600E [46,47].”
Unveiling acquired resistance to anti-EGFR therapies in colorectal cancer: a long and winding road
Ríos-Hoyo, A., Monzonís, X., Vidal, J., Linares, J., & Montagut, C. O. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1398419 · Cited by 47 · cited 1×
“Currently, an ongoing phase 3 first-line trial (NCT06252649, CodeBreaK 301) is evaluating whether the addition of anti-KRAS targeted therapy (Sotora-sib) to the first line setting is a possible strategy to overcome resistance (Table 1) [61] Figure 1.”
Anti-EGFR Antibodies in the Management of Advanced Colorectal Cancer
Kasi, P. M., Afable, M. G., Herting, C. J., Lukanowski, M., & Jin, Z. (2023) · The Oncologist · doi:10.1093/oncolo/oyad262 · Cited by 47 · cited 2×
“Tumors that retain the wild-type presentation of these genes are considered eligible for epidermal growth factor receptor (EGFR) blockade with cetuximab or panitumumab, particularly in left-sided tumors [10,11].”
Loree, J. M., Wang, Y., Syed, M. A., Sorokin, A. V., Coker, O., Xiu, J., Weinberg, B. A., Vanderwalde, A. M., Tesfaye, A., Raymond, V. M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0180 · Cited by 43
Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance
Ali, M., Kaltenbrun, E., Anderson, G. R., Stephens, S. J., Arena, S., Bardelli, A., Counter, C. M., & Wood, K. C. (2017) · Nature Communications · doi:10.1038/ncomms15617 · Cited by 43 · cited 1×
“These alterations may arise from the expansion of pre-existing mutated clones or from the emergence of new mutations induced by the selective pressure exerted by prolonged use of agents such as cetuximab or panitumumab [129,130].”
Molecular Predictors of Efficacy to Anti-EGFR Agents in Colorectal Cancer Patients
Ruzzo, A., Graziano, F., Canestrari, E., & Magnani, M. (2010) · Current Cancer Drug Targets · doi:10.2174/156800910790980205 · Cited by 42 · cited 1×
“Recognizing that EGFR’s extracellular domain is both accessible and central to this cascade provided the rationale for developing high-affinity monoclonal antibodies that occupy the ligand pocket, prevent dimerization, and promote receptor down-regulation [35].”
Zheng, Y., Lou, S., Lu, J., Zheng, F., Tang, Y., Zhang, E.-J., Cui, S., & Zhao, H. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06848-7 · Cited by 39
Clifton, K., Rich, T. A., Parseghian, C., Raymond, V. M., Dasari, A., Pereira, A. A. L., Willis, J., Loree, J. M., Bauer, T. M., Chae, Y. K., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00141 · Cited by 37 · cited 2×
“Intratumoral heterogeneity is a central feature of colorectal cancer and decisively influences this acquired resistance [108].”
Tissue-agnostic cancer therapies: promise, reality, and the path forward
Subbiah, V. (2025) · Nature Communications · doi:10.1038/s41467-025-60369-1 · Cited by 37
Ciardiello, F., & Normanno, N. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0261 · Cited by 36 · cited 1×
“This pathway redundancy resistance strategy occurs when an amplification of a parallel receptor compensates for the inhibition of EGFR [69].”
Bekaii-Saab, T. S., Lach, K., Hsu, L.-I., Siadak, M., Stecher, M., Ward, J., Beckerman, R., & Strickler, J. H. (2023) · The Oncologist · doi:10.1093/oncolo/oyad200 · Cited by 36
Shitara, K., Muro, K., Watanabe, J., Yamazaki, K., Ohori, H., Shiozawa, M., Yasui, H., Oki, E., Sato, T., Naito, T., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.2023.41.4_suppl.11 · Cited by 35
Lu, X., Li, Y., Li, Y., Zhang, X., Shi, J., Feng, H., Yu, Z., & Gao, Y. (2023) · BMC Cancer · doi:10.1186/s12885-023-11600-z · Cited by 33 · cited 3×
“Amplification of the MET proto-oncogene, encoding another receptor tyrosine kinase, represents an additional mechanism of bypass signaling [84].”
InfluentialSelective AKT Inhibition by MK-2206 Represses Colorectal Cancer-Initiating Stem Cells
Malkomes, P. T. Z., Lunger, I., Luetticke, A., Oppermann, E., Haetscher, N., Serve, H. L., Holzer, K., Bechstein, W. O., & Rieger, M. A. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5218-z · Cited by 33 · cited 1×
“NTRK and RET fusions are distinct gene rearrangements involving receptor tyrosine kinases that lead to constitutive activation of downstream signaling pathways in mCRC [102,103].”
Erve, I. V. ’., Greuter, M. J. E., Bolhuis, K., Vessies, D. C. L., Leal, A., Vink, G. R., van den Broek, D. A., Velculescu, V. E., Punt, C. J. A., Meijer, G. A., et al. (2020) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2020.09.002 · Cited by 33
Modeling colorectal cancer evolution
Niida, A., Mimori, K., Shibata, T., & Miyano, S. (2021) · Journal of Human Genetics · doi:10.1038/s10038-021-00930-0 · Cited by 33 · cited 1×
“The identification of the main molecular alterations responsible for this resistance has been a priority for the development of personalized therapeutic strategies, prompting a series of clinical trials aimed at understanding the mechanisms involved in acquired resistance [125–127].”
Chuang, J., Wang, C., Guo, Y., Valenzuela, V., Wu, J., & Fakih, M. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.12.003 · Cited by 33
da Silva, L. F. L., Saldanha, E. F., de Menezes, J. S. A., Pereira, L. H., dos Santos, J. A. R. D. B., Buonopane, I. R., de Souza, E. M., de Menezes, C. U. G., & Junior, G. L. L. (2025) · The Oncologist · doi:10.1093/oncolo/oyae344 · Cited by 32
Hechtman, J. F., Sadowska, J., Huse, J. T., Borsu, L. A., Yaeger, R. D., Shia, J., Vakiani, E., Ladanyi, M., & Arcila, M. E. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0062-t · Cited by 30 · cited 1×
“Patients harboring AKT1 activating mutations often exhibit inferior response outcomes [98].”
MET amplification, expression, and exon 14 mutations in colorectal adenocarcinoma
Zhang, M., Li, G., Sun, X., Ni, S., Tan, C., Xu, M., Huang, D., Ren, F., Li, D., Wei, P., et al. (2018) · Human Pathology · doi:10.1016/j.humpath.2018.03.024 · Cited by 28 · cited 1×
“[89].”
Goodwin, R. A., Jonker, D. J., Chen, E. X., Kennecke, H. F., Cabanero, M., Tsao, M., Vickers, M. M., Bohemier, C., Lim, H. J., Ritter, H. D., et al. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00814-3 · Cited by 27
Genetic alterations shaping tumor response to anti-EGFR therapies
Vaquero, J., Pavy, A., Gonzalez‐Sanchez, E., Meredith, M., Arbelaiz, A., & Fouassier, L. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100863 · Cited by 26 · cited 1×
“As detailed in previous sections, alterations such as HER2 and MET amplifications, NTRK , ROS1 , ALK , and RET fusions, PIK3CA exon 20 and MAP2K1 mutations, as well as PTEN loss, activate alternative signaling pathways that circumvent EGFR -blockade [143].”
Bianchi, A. S., Siena, S., Tonini, G., Bardelli, A., & Santini, D. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.10.006 · Cited by 25
NTRK fusions in colorectal cancer: clinical meaning and future perspective
Ratti, M., Grizzi, G., Passalacqua, R., Lampis, A., Cereatti, F., Grassia, R., & Hahne, J. C. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1978070 · Cited by 25 · cited 1×
“Supporting this idea, a large circulating tumor DNA (ctDNA) analysis of 3808 patients with advanced CRC detected gene fusions in 1.1% of cases, most commonly involving RET , FGFR3 , and ALK [107].”
InfluentialCruz-Duarte, R., de Almeida, C. R., Negrão, M., Fernandes, A., Borralho, P., Sobral, D., Gallego-Paez, L. M., Machado, D., Gramaça, J., Vílchez, J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1992 · Cited by 25
Pietrantonio, F., Bergamo, F., Rossini, D., Ghelardi, F., Grandis, M. C. D., Germani, M. M., Barsotti, G., Formica, V., Frassineti, G. L., Boscolo, G., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113396 · Cited by 24 · cited 2×
“These findings underscore the clinical utility of ctDNA not only as a biomarker but as a real-time decision-making instrument in the management of anti-EGFR resistance [17].”
Jacob, J., Anami, Y., High, P. C., Liang, Z., Subramanian, S., Ghosh, S. C., AghaAmiri, S., Guernsey-Biddle, C., Tran, H., Rowe, J. H., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-0798 · Cited by 22 · cited 1×
“Concurrently, emerging modalities, including bispecific antibodies, EGFR-directed antibody–drug conjugates, and RNA-based therapeutics will expand the options for patients with resistant disease [53,158,165,166].”
Stahler, A., Kind, A. J., Sers, C., Mamlouk, S., Müller, L., Karthaus, M., Fruehauf, S., Graeven, U., von Weikersthal, L. F., Sommerhäuser, G., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3023 · Cited by 21
Overview of the role of liquid biopsy in cancer management
Assi, T., Khoury, R., Ibrahim, R., Baz, M., Ibrahim, T., & Cesne, A. L. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101702 · Cited by 21 · cited 1×
“…DNA from multiple sites, enables real-time monitoring of tumor evolution and treatment response (including early detection of resistance), serves as a sensitive marker for minimal residual disease (MRD) post-treatment to predict recurrence, and potentially offers faster turnaround times [150–153].”
Napolitano, S., Ciardiello, D., Cioli, E., Martinelli, E., Troiani, T., Zampino, M. G., Fazio, N., Vita, F. D., Ciardiello, F., & Martini, G. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102905 · Cited by 20 · cited 1×
“Similarly, the BRAFV600E mutation acts further downstream to provide a continuous growth signal independent of receptor activation [29,30].”
Advances and challenges in targeted therapies for HER2-amplified colorectal cancer
Pizzamiglio, M., Soulabaille, A., Lahlou, W., Pilla, L., Zaanan, A., & Taïeb, J. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115471 · Cited by 20 · cited 1×
“HER2 amplification is a well-established mechanism of resistance to anti-EGFR therapy, occurring in approximately 5–7% of RAS/BRAF wild-type mCRC cases [66].”
Prospective Biomarker Study in Advanced RAS Wild-Type Colorectal Cancer: POSIBA Trial (GEMCAD 10-02)
García‐Albéniz, X., Alonso, V., Escudero, P., Méndez, M., Gallego-Plazas, J., Rodríguez, J. R., Salud, A., Fernández-Plana, J., Manzano, H., Zanui, M., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0728 · Cited by 19
Cancer-Associated Fibroblast Proteins as Potential Targets against Colorectal Cancers
Shah, R., Johnson, K. A., Lippert, A. E. L., Kraus, S. G., Emmerich, P. B., Pasch, C. A., Zhang, W., Matkowskyj, K. A., LeBeau, A. M., & Deming, D. A. (2024) · Cancers · doi:10.3390/cancers16183158 · Cited by 18 · cited 1×
“By sustaining parallel pathways despite EGFR blockade, these stromal interactions highlight the importance of considering the tumor microenvironment as a therapeutic target [140,141].”
Lièvre, A., Ouine, B., Canet, J., Cartier, A., Amar, Y., Cacheux, W., Mariani, O., Guimbaud, R., Selves, J., Lecomte, T., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.353 · Cited by 18
Colorectal cancer: Review of signaling pathways and associated therapeutic strategies
Leiphrakpam, P. D., Rajappa, S. J., Krishnan, M., Batra, R., Murthy, S. S., & Are, C. (2023) · Journal of Surgical Oncology · doi:10.1002/jso.27295 · Cited by 18 · cited 1×
“A retrospective cohort study of the clinico-pathologic and molecular profile to analysis of AKT1 E17K -mutated CRC revealed a strong association with mucinous histology ( p = 0.0006) and frequent co-occurrence with BRAF V600E and KRAS mutations ( p = 0.0001) [97].”
InfluentialKast, J., Dutta, S., & Upreti, V. V. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01809-4 · Cited by 18 · cited 1×
“Cetuximab is a chimeric immunoglobulin G-one molecule; panitumumab is a fully human immunoglobulin G-two molecule with lower intrinsic immunogenicity [36,37].”
Pisheh, L., Matis, S., Taglieri, M., Gregorio, L. D., Benelli, R., & Poggi, A. D. (2024) · Cancers · doi:10.3390/cancers16071256 · Cited by 18
Kim, J. S., Kim, J. E., Kim, K., Lee, J., Park, J. O., Lim, H. Y., Park, Y. S., Kang, W. K., & Kim, S. T. (2017) · Journal of Cancer · doi:10.7150/jca.19458 · Cited by 17
Right-Sided Versus Left-Sided Colon Cancer—A 5-Year Single-Center Observational Study
Szostek, J., Serafin, M., Mąka, M., Jabłońska, B., & Mrowiec, S. (2025) · Cancers · doi:10.3390/cancers17030537 · Cited by 17 · cited 1×
“This trend is both concerning and clinically relevant in the context of this review, as left-sided tumors typically demonstrate greater responsiveness to anti-EGFR therapy [3,4].”
Cruz-Duarte, R., de Almeida, C. R., Negrão, M., Fernandes, A., Borralho, P., Sobral, D., Gallego-Paez, L. M., Machado, D., Gramaça, J., Vı́lchez, J. M., et al. (2022) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · Cited by 16
Dankner, M., Rousselle, E., Petrecca, S., Fabi, F., Nowakowski, A., Lazaratos, A.-M., Rajadurai, C. V., Stein, A. J. B., Bian, D., Tai, P., et al. (2025) · JCO Precision Oncology · doi:10.1200/po.24.00199 · Cited by 13
Nakamura, Y., Okamoto, W., Sawada, K., Komatsu, Y., Kato, K., Taniguchi, H., Kato, T., Nishina, T., Esaki, T., Nomura, H., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx393.137 · Cited by 11
Gluing GAP to RAS Mutants: A New Approach to an Old Problem in Cancer Drug Development
Ranđelović, I., Nyíri, K., Koppány, G., Baranyi, M., Tóvári, J., Kigyós, A., Tímár, J., Vértessy, B. G., & Grolmusz, V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052572 · Cited by 10
Optimizing Access to Liquid Biopsy in the Present and Future Cancer Landscape
Medford, A. J., & Ellisen, L. W. (2024) · JCO Precision Oncology · doi:10.1200/po.23.00609 · Cited by 10 · cited 1×
“Outside of validated settings such as RAS testing for anti-EGFR therapy or minimal residual disease detection, the impact of ctDNA-guided interventions on overall survival remains to be established [164].”
Kopetz, S., Boni, V., Kato, K., Raghav, K. P. S., Pallis, A. G., Habermehl, C., Galipelli, S., Courlet, P., & Rodriguez-Rivera, I. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.2024.42.16_suppl.3000 · Cited by 9
Fucà, G., Raimondi, A., Prisciandaro, M., Lonardi, S., Cremolini, C., Ratti, M., Clavarezza, M., Murialdo, R., Bianchi, A. S., Smiroldo, V., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyab012 · Cited by 9
Lenz, H., Overman, M. J., Cutsem, E. V., Limón, M. L., Wong, K. Y. M., Hendlisz, A., Aglietta, M., Alfonso, P. G., Neyns, B., Gelsomino, F., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.2024.42.3_suppl.97 · Cited by 8
Towards Multiomics-Based Dissection of Anti-EGFR Sensitivity in Colorectal Cancer
Randon, G., & Pietrantonio, F. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1954 · Cited by 7 · cited 1×
“…due to challenges in obtaining sufficient quantity and quality of tumor tissue, often compounded by tumor location or the patient’s condition [122,148]. ctDNA, small DNA fragments shed by tumors into the bloodstream, allows for non-invasive liquid biopsies for genomic profiling via molecular…”
Abdelgadir, O., Kuo, Y., Okorodudu, A. O., Khan, M. F., Cheng, Y., & Dong, J. (2025) · Diagnostics · doi:10.3390/diagnostics15020142 · Cited by 7 · cited 1×
“Activating mutations at KRAS codons 12 and 13 (exon 2), as well as in KRAS exons 3–4 and NRAS exons 2–4, impair GTP hydrolysis and lock RAS in its active, GTP-bound form [59].”
Argilés, G., Jungels, C., García‐Carbonero, R., García, M. D., Bendell, J. C., Tabernero, J. M., Békradda, M., van Bueren, J. J. L., Bol, K., Stalbovskaya, V., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.3_suppl.62 · Cited by 7 · cited 1×
“…conjugates (ADCs) that link EGFR recognition to cytotoxic payloads, bispecific antibodies that co-target EGFR and c-MET or EGFR and HER3, and small interfering RNA nanocomplexes that selectively silence mutant RAS are entering early-phase trials, while their results are awaited [52–57].”
Kim, T. W., Price, T. J., Grasselli, J., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco.2025.43.4_suppl.tps326 · Cited by 6 · cited 1×
“…nor panitumumab, alone or combined with chemotherapy, improved OS (HR, 0.91; 95% CI, 0.62–1.34; p = 0.63), PFS (HR, 0.88; 95% confidence interval (CI), 0.67–1.14; p = 0.33) or (relative risk, 1.31; 95% CI 0.83–2.08, p = 0.25) in BRAF -mutant mCRC compared with chemotherapy ± bevacizumab [62].”
Influentialda Silva, L. F. L., Saldanha, E. F., da Conceição, L. D., Noronha, M. M., Silva, M. V., & Peixoto, R. D. (2024) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-024-01152-1 · Cited by 5
Self-citationCirculating Tumor DNA as a Biomarker for Outcomes Prediction in Colorectal Cancer Patients
Petrillo, A., Salati, M., Trapani, D., & Ghidini, M. (2020) · Current Drug Targets · doi:10.2174/1389450121999201103194248 · Cited by 5
Napolitano, S., Parikh, A. R., Henry, J. T., Parseghian, C. M., Willis, J. A., Raghav, K. P. S., Morris, V. K., Johnson, B., Kee, B. K., Dasari, A. N., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.23.00228 · Cited by 5 · cited 1×
“False-negative results may occur in cases with low tumor burden, limited tumor shedding, or metastases located in compartments with restricted access to the bloodstream, such as the peritoneum or central nervous system [159,160].”
Mauri, G., Patelli, G., Gori, V., Lauricella, C., Mussolin, B., Amatu, A., Bencardino, K. B., Tosi, F., Bonazzina, E. F., Bonoldi, E., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1030232 · Cited by 5 · cited 1×
“Additionally, although clinical trials have shown the efficacy of combining anti-MEK and anti-EGFR therapies in mCRC with MEK-driven resistance, data specifically addressing resistance in patients with MAP2K1 mutations remain scarce [94].”
Alfonso, P. G., Valladares‐Ayerbes, M., Martín, A. J. M., Herrero, R. M., Muñoz, E. G., & Prat-Llorens, G. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2477192 · Cited by 5
Religa, P., Łazarczyk, M., Mickael, M., & Skiba, D. S. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.03.044 · Cited by 5 · cited 1×
“Interestingly, the traditional expansion of ‘MET’ as ‘mesenchymal–epithelial transition factor’ is a common misnomer [85]; the official HGNC designation is ‘MET proto-oncogene,’ and the original ‘met’ acronym was a neutral label from the MNNG-HOS transforming gene [86].”
Shen, L., Parseghian, C. M., Zhang, Y., Chen, Z., Qin, Y., Zhang, W., Deng, Y., Pan, H., Gu, S., Li, C., et al. (2025) · Cancer Research · doi:10.1158/1538-7445.am2025-ct168 · Cited by 2
Kim, S. T., Lee, S. J., Park, J. O., Lim, H. Y., Kang, W. K., Park, Y. S., & Lee, J. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.e15153 · Cited by 1
Cited by
Beyond the membrane: rethinking EGFR signaling in physiology and cancer
Jendrisek, G., Mesa, D., Conte, A., Malabarba, M. G., & Sigismund, S. (2026) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-06036-6 · Cited by 18
Agüera-Sánchez, A., Ros, E. P., Martínez‐Martínez, I., & García-Molina, F. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16010048 · Cited by 11
“It is now firmly established that tumors harboring activating mutations in KRAS or NRAS exon 2, 3, or 4 do not respond to anti-EGFR therapy, because the down-stream signaling is constitutively active [131].”
Clinical trials of bispecific antibody therapy for colorectal cancer: advanced and next steps
Shao, W., Liu, Y., Huang, L., Lu, S., Zhai, Y., Xiong, Y., Chen, N., Ye, P., & Lv, Q. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1758251 · Cited by 6
Nardone, V., Patanè, V., Marinelli, L., D’Ambrosio, L., Tufo, S. D., Chiara, M. D., Brunese, M. C., Rubini, D., Grassi, R., Russo, A., et al. (2025) · Diagnostics · doi:10.3390/diagnostics15222914 · Cited by 5
Abbas, N., Mourad, M., Smaily, H., Al Mahmasani, L., & Shamseddine, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27073265 · Cited by 4
“Patients selected through this extended molecular approach will achieve higher response rates and improved clinical outcomes [148].”
Metadata
- Authors
- Leite, L. F., Noronha, M. M., de Menezes, J. S. A., da Conceição, L. D., Almeida, L. F. C., Cappellaro, A. P., Belotto, M., Biachi de Castria, T., Peixoto, R. D., & Megid, T. B. C.
- Affiliations
- Universidade Federal Fluminense (BR)
- Universidade Federal do Ceará (BR)
- Department of Medical Sciences, Universidade Federal da Bahia, Salvador 40170-110, BA, Brazil
- Department of Medical Sciences, Universidade Federal Fluminense, Niteroi 24220-140, RJ, Brazil
- Centro Universitário Maurício de Nassau (BR)
- Department of Surgery, Hospital 9 de Julho, São Paulo 01409-002, SP, Brazil
- Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
- BC Cancer Agency (CA)
- Université de Sherbrooke (CA)
- Corresponding author
- Megid, Thais Baccili Cury
- ORCID
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2025-08-27
- Volume
- 17
- Issue
- 17
- Pages
- 2804
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC12427569
- OpenAlex
- W4413757473
- Cited by
- 32
- References
- 159
- Citations by year
- 2026: 26 · 2025: 6
- FWCI
- 3.76
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- anti-EGFR therapy, metastatic colorectal cancer, EGFR inhibitors, acquired drug resistance, primary resistance, comprehensive molecular profiling, ERBB2 amplification, MET amplification, PI3K/Akt signaling, circulating tumor DNA, liquid biopsy, clonal evolution, precision oncology, bispecific antibodies, antibody-drug conjugates, RNA therapeutics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.